These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31144396)

  • 1. Health-related quality of life among people who use methamphetamine.
    McKetin R; Voce A; Burns R; Shanahan M
    Drug Alcohol Rev; 2019 Jul; 38(5):503-509. PubMed ID: 31144396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a discrete negative symptom syndrome in people who use methamphetamine?
    Voce A; Burns R; Castle D; Calabria B; McKetin R
    Compr Psychiatry; 2019 Aug; 93():27-32. PubMed ID: 31301605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of psychotic symptoms among methamphetamine users.
    McKetin R; McLaren J; Lubman DI; Hides L
    Addiction; 2006 Oct; 101(10):1473-8. PubMed ID: 16968349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
    JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hostility among methamphetamine users experiencing psychotic symptoms.
    McKetin R; McLaren J; Lubman DI; Hides L
    Am J Addict; 2008; 17(3):235-40. PubMed ID: 18464001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial.
    McKETIN R; Quinn B; Higgs P; Berk M; Dean OM; Turner A; Kelly PJ; Lubman DI; Carter G; Baker AL; Manning V; Thomas T; Bathish R; Raftery D; Saunders L; Wrobel A; Meehan A; Sinclair B; Reid D; Arunogiri S; Hill H; Cordaro F; Dietze PM
    Drug Alcohol Rev; 2021 Nov; 40(7):1249-1255. PubMed ID: 33022140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.
    McKetin R; Baker AL; Dawe S; Voce A; Lubman DI
    Psychiatry Res; 2017 May; 251():349-354. PubMed ID: 28282630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid use.
    McKetin R; Kelly E; McLaren J; Proudfoot H
    Drug Alcohol Rev; 2008 Sep; 27(5):482-9. PubMed ID: 18608459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impulsivity predicts poorer improvement in quality of life during early treatment for people with methamphetamine dependence.
    Rubenis AJ; Fitzpatrick RE; Lubman DI; Verdejo-Garcia A
    Addiction; 2018 Apr; 113(4):668-676. PubMed ID: 28987070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users.
    McKetin R; Gardner J; Baker AL; Dawe S; Ali R; Voce A; Leach LS; Lubman DI
    Psychiatry Res; 2016 Apr; 238():166-171. PubMed ID: 27086229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The profile of psychiatric symptoms exacerbated by methamphetamine use.
    McKetin R; Dawe S; Burns RA; Hides L; Kavanagh DJ; Teesson M; McD Young R; Voce A; Saunders JB
    Drug Alcohol Depend; 2016 Apr; 161():104-9. PubMed ID: 26874915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
    Kinner SA; Degenhardt L
    Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes for methamphetamine users receiving outpatient counselling from the Stimulant Treatment Program in Australia.
    McKetin R; Dunlop AJ; Holland RM; Sutherland RA; Baker AL; Salmon AM; Hudson SL
    Drug Alcohol Rev; 2013 Jan; 32(1):80-7. PubMed ID: 22642414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Socio-demographic factors associated with methamphetamine treatment contact among dependent methamphetamine users in Sydney, Australia.
    McKetin R; Kelly E
    Drug Alcohol Rev; 2007 Mar; 26(2):161-8. PubMed ID: 17364851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence.
    Willi TS; Honer WG; Thornton AE; Gicas K; Procyshyn RM; Vila-Rodriguez F; Panenka WJ; Aleksic A; Leonova O; Jones AA; MacEwan GW; Barr AM
    Psychiatry Res; 2016 Jun; 240():336-342. PubMed ID: 27138828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Najman JM; Dawe S; Butterworth P; Baker AL
    Addiction; 2014 May; 109(5):798-806. PubMed ID: 24400972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.
    McKetin R; Ross J; Kelly E; Baker A; Lee N; Lubman DI; Mattick R
    Drug Alcohol Rev; 2008 May; 27(3):277-85. PubMed ID: 18368609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence.
    Alexander PD; Gicas KM; Willi TS; Kim CN; Boyeva V; Procyshyn RM; Smith GN; Thornton AE; Panenka WJ; Jones AA; Vila-Rodriguez F; Lang DJ; William MacEwan G; Honer WG; Barr AM
    Psychopharmacology (Berl); 2017 May; 234(9-10):1535-1547. PubMed ID: 28190084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs.
    Smirnov A; Kemp R; Ward J; Henderson S; Williams S; Dev A; Najman JM
    Drug Alcohol Rev; 2016 Sep; 35(5):611-9. PubMed ID: 27241554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population.
    Lappin JM; Roxburgh A; Kaye S; Chalmers J; Sara G; Dobbins T; Burns L; Farrell M
    Int J Drug Policy; 2016 Dec; 38():16-20. PubMed ID: 27842249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.